FTC Study of Authorized Generics Gets Off the Ground: Now What?
This article was originally published in RPM Report
Executive Summary
A Federal Trade Commission analysis of the competitive impact of authorized generics has been in limbo for months. The agency recently received approval to go ahead with the controversial study from the executive branch. What should drug companies expect to receive in the mail?